TuHURA Biosciences, Inc.
HURA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001498382
No open-market purchases or sales by TuHURA Biosciences, Inc. insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $21.0M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 14, 2026, 1:24 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | Sep 18, 2023 | Sep 27, 2022 |
| Revenue | $0 | $0 | – | – | – |
| Operating expenses | $31.8M | $17.6M | $8.45M | $14.8M | $22.7M |
| Research and development | $20.5M | $13.3M | $2.66M | $9.31M | $15.2M |
| Selling, general and administrative | $7.58M | $4.31M | $5.79M | $5.49M | $7.51M |
| Interest expense | $625.3K | $4.14M | – | – | – |
| Income tax | $1.60K | $3.77K | – | – | – |
| Net income | -$30.1M | -$21.7M | -$8.32M | -$14.6M | -$22.7M |
| EPS, basic | $-0.63 | $-1.21 | $-0.32 | $-9.27 | $-0.52 |
| EPS, diluted | $-0.63 | $-1.21 | – | – | – |
| Weighted shares, basic | 47.9M | 18.7M | 26.4M | 1.62M | 48.7M |
| Weighted shares, diluted | 47.9M | 18.7M | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | Sep 18, 2023 | Sep 27, 2022 |
| Cash and equivalents | $3.62M | $12.7M | $4.91M | $1.53M | $11.8M |
| Total current assets | $4.62M | $19.6M | $5.53M | $3.27M | $13.3M |
| Property, plant and equipment | $300.6K | $123.4K | $674.0K | $709.0K | $90.0K |
| Goodwill | $10.7M | – | – | – | – |
| Total assets | $27.4M | $20.0M | $6.20M | $3.98M | $15.9M |
| Accounts payable | $3.77M | $3.15M | – | – | – |
| Total current liabilities | $5.92M | $5.33M | $2.26M | $3.08M | $3.99M |
| Total liabilities | $6.42M | $5.37M | $2.44M | $3.25M | $4.15M |
| Shareholders' equity | $20.9M | $14.6M | $3.76M | $731.0K | $11.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | Sep 18, 2023 | Sep 27, 2022 |
| Operating cash flow | -$27.6M | -$14.7M | -$7.18M | -$11.9M | -$20.4M |
| Capital expenditures | $76.1K | $57.9K | – | – | – |
| Free cash flow | -$27.7M | -$14.8M | – | – | – |
| Depreciation and amortization | $71.3K | $116.7K | – | – | – |
| Stock-based compensation | $6.42M | $1.96M | $607.0K | $1.49M | $2.25M |
| Investing cash flow | -$1.34M | -$6.05M | -$20.0K | -$232.0K | – |
| Financing cash flow | $19.9M | $29.8M | $10.6M | $1.85M | $21.6M |
| Net change in cash | -$9.04M | $8.99M | $3.37M | -$10.2M | $1.24M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 10, 2026 | 65.8M | +28.3% | SEC |
| Aug 11, 2026 | 63.7M | +27.3% | SEC |
| May 12, 2026 | 63.7M | +45.8% | SEC |
| Apr 24, 2026 | 63.7M | +45.8% | SEC |
| Mar 23, 2026 | 63.6M | +45.6% | SEC |
| Nov 11, 2025 | 51.3M | −99.9% | SEC |
| Aug 11, 2025 | 50.0M | −99.9% | SEC |
| May 12, 2025 | 43.7M | −99.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Jun 30, 2021, from 13F share counts: 1-for-50 in Q4 2022.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.